Filing Flows › Camp4 Therapeutics (CAMP) › Q3 2026
Camp4 Therapeutics (CAMP) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Camp4 Therapeutics (CAMP) reported revenue of $1.9M for the third quarter 2026 (Q3 2026), +139% from a year earlier and +7% from the quarter before. Operating margin was -738.8%.
Camp4 Therapeutics, Q3 2026: revenue $1.9M (+139% year over year), operating margin -738.8%, net loss $29.0M, operating cash flow −$8.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.9M | +7% | +139% |
| Operating profit | −$14.0M | — | — |
| Net earnings | −$29.0M | — | — |
| Operating cash flow | −$8.2M | — | — |
What changed
Revenue was $1.9M in Q3 2026, up 139% year over year and up 7% from the previous quarter.
Operating costs exceeded revenue by $14.0M, an operating margin of -738.8%. Total costs grew 10% against revenue growth of 139%. The fastest-growing cost line was Research & development (+16%). The quarter ended with a net loss of $29.0M, narrower than the previous quarter's $33.5M loss. Net interest and other expense of $14.9M was the main reason.
Operating cash flow was −$8.2M. Non-cash charges added back $523K of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items added $18.2M. Capital expenditures of $740K exceeded it, leaving free cash flow of −$8.9M.
Questions
What was Camp4 Therapeutics' revenue in the third quarter 2026?
Camp4 Therapeutics (CAMP) reported revenue of $1.9M for the third quarter 2026 (Q3 2026), +139% from a year earlier and +7% from the quarter before.
Was Camp4 Therapeutics profitable in the third quarter 2026?
Operating loss was $14.0M (-738.8% of revenue) and net loss $29.0M.
Source: Camp4 Therapeutics 10-Q on SEC EDGAR.